Cormorant Asset Management as of Dec. 31, 2014
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 70 positions in its portfolio as reported in the December 2014 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Receptos | 12.1 | $79M | 642k | 122.51 | |
Puma Biotechnology (PBYI) | 6.4 | $42M | 220k | 189.27 | |
Celgene Corporation | 5.2 | $34M | 300k | 111.86 | |
Ovascience | 5.1 | $33M | 747k | 44.22 | |
Alkermes (ALKS) | 4.1 | $26M | 450k | 58.56 | |
Neurocrine Biosciences (NBIX) | 3.4 | $22M | 1.0M | 22.34 | |
Dyax | 3.2 | $21M | 1.5M | 14.06 | |
Ardelyx (ARDX) | 3.1 | $20M | 1.1M | 18.89 | |
Quotient | 3.0 | $20M | 1.1M | 18.00 | |
Regulus Therapeutics | 2.7 | $18M | 1.1M | 16.04 | |
Sorrento Therapeutics (SRNE) | 2.7 | $18M | 1.8M | 10.07 | |
Portola Pharmaceuticals | 2.6 | $17M | 600k | 28.32 | |
Chimerix (CMRX) | 2.5 | $16M | 400k | 40.26 | |
Bristol Myers Squibb (BMY) | 2.3 | $15M | 250k | 59.03 | |
Kite Pharma | 2.3 | $15M | 255k | 57.67 | |
Omeros Corporation (OMER) | 2.2 | $14M | 582k | 24.78 | |
Karyopharm Therapeutics (KPTI) | 2.2 | $14M | 385k | 37.43 | |
Keryx Biopharmaceuticals | 2.2 | $14M | 1.0M | 14.15 | |
Tesaro | 1.7 | $11M | 300k | 37.19 | |
Dex (DXCM) | 1.7 | $11M | 200k | 55.05 | |
BioCryst Pharmaceuticals (BCRX) | 1.5 | $9.7M | 800k | 12.16 | |
Acceleron Pharma | 1.5 | $9.7M | 250k | 38.96 | |
Synageva Biopharma | 1.4 | $9.3M | 100k | 92.79 | |
Novavax | 1.4 | $8.9M | 1.5M | 5.93 | |
Sangamo Biosciences (SGMO) | 1.2 | $7.6M | 500k | 15.21 | |
Alder Biopharmaceuticals | 1.1 | $7.3M | 250k | 29.09 | |
Heron Therapeutics (HRTX) | 1.1 | $7.0M | 700k | 10.06 | |
Nektar Therapeutics (NKTR) | 1.1 | $7.0M | 450k | 15.50 | |
Acelrx Pharmaceuticals | 1.0 | $6.7M | 1.0M | 6.73 | |
Advaxis | 1.0 | $6.7M | 840k | 8.01 | |
Aptose Biosciences | 1.0 | $6.4M | 1.1M | 5.91 | |
Eagle Pharmaceuticals (EGRX) | 1.0 | $6.2M | 400k | 15.50 | |
China Biologic Products | 0.9 | $6.1M | 90k | 67.23 | |
Ultragenyx Pharmaceutical (RARE) | 0.8 | $5.3M | 120k | 43.88 | |
Auspex Pharmaceuticals | 0.8 | $5.2M | 100k | 52.48 | |
Array BioPharma | 0.7 | $4.7M | 1.0M | 4.73 | |
Versartis | 0.7 | $4.5M | 200k | 22.45 | |
Immune Design | 0.7 | $4.3M | 140k | 30.78 | |
Nanostring Technologies (NSTGQ) | 0.6 | $4.2M | 300k | 13.93 | |
Rockwell Medical Technologies | 0.6 | $4.1M | 400k | 10.28 | |
Bristol-myers Squibb | 0.6 | $3.7M | 5.0k | 740.00 | |
Coherus Biosciences (CHRS) | 0.6 | $3.6M | 222k | 16.32 | |
Dermira | 0.6 | $3.6M | 200k | 18.11 | |
Avalanche Biotechnologies In | 0.5 | $3.5M | 65k | 54.00 | |
Lipocine | 0.5 | $3.5M | 667k | 5.26 | |
Glycomimetics (GLYC) | 0.5 | $3.4M | 472k | 7.20 | |
Dicerna Pharmaceuticals | 0.5 | $3.3M | 200k | 16.47 | |
Agenus | 0.5 | $3.2M | 800k | 3.97 | |
Forward Pharma A/s | 0.5 | $3.1M | 150k | 20.83 | |
Genvec | 0.4 | $2.8M | 1.3M | 2.08 | |
Cerulean Pharma | 0.4 | $2.8M | 450k | 6.22 | |
Kindred Biosciences | 0.4 | $2.6M | 350k | 7.45 | |
Aquinox Pharmaceuticals | 0.3 | $2.3M | 300k | 7.50 | |
Recro Pharma | 0.3 | $2.0M | 700k | 2.86 | |
Cellectar Biosciences | 0.2 | $1.6M | 530k | 3.09 | |
Celsus Therapeutics Plc sponsored adr ne | 0.2 | $1.4M | 300k | 4.80 | |
Akebia Therapeutics (AKBA) | 0.2 | $1.4M | 118k | 11.64 | |
Bellicum Pharma | 0.2 | $1.4M | 60k | 23.03 | |
Applied Genetic Technol Corp C | 0.2 | $1.3M | 61k | 21.02 | |
Galectin Therapeutics (GALT) | 0.2 | $1.1M | 312k | 3.47 | |
Minerva Neurosciences | 0.2 | $1.1M | 175k | 6.02 | |
Veracyte (VCYT) | 0.1 | $968k | 100k | 9.66 | |
Scynexis | 0.1 | $998k | 100k | 9.98 | |
Curis | 0.1 | $900k | 600k | 1.50 | |
Agile Therapeutics | 0.1 | $921k | 150k | 6.14 | |
Ptc Therapeutics I (PTCT) | 0.1 | $518k | 10k | 51.80 | |
Epirus Biopharmaceuticals In | 0.1 | $425k | 75k | 5.67 | |
Cellectar Biosciences Inc *w exp 08/19/201 | 0.1 | $424k | 530k | 0.80 | |
Nevro (NVRO) | 0.1 | $387k | 10k | 38.70 | |
Sage Therapeutics (SAGE) | 0.0 | $37k | 1.0k | 37.00 |